Very Long Chain Marine <i>n</i>-3 Polyunsaturated Fatty Acids in Atherothrombotic Heart Disease. A Brief Review, with a Focus on Metabolic Effects
The global burden of atherothrombotic heart disease should be considered as a life-style disorder where differences in dietary habits and related risk factors like limited physical activity and adiposity together play important roles. Related metabolic changes have been scientifically elucidated in...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-09-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/12/10/3014 |
| _version_ | 1797552151900192768 |
|---|---|
| author | Harald Arnesen Peder L. Myhre Ingebjørg Seljeflot |
| author_facet | Harald Arnesen Peder L. Myhre Ingebjørg Seljeflot |
| author_sort | Harald Arnesen |
| collection | DOAJ |
| description | The global burden of atherothrombotic heart disease should be considered as a life-style disorder where differences in dietary habits and related risk factors like limited physical activity and adiposity together play important roles. Related metabolic changes have been scientifically elucidated in recent decades, and the role of the very-long-chain marine fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been much focused on, especially their possible effects on processes like inflammation and thrombosis. In the present brief review of related metabolic mechanisms, the effects of these fatty acids in a clinical setting have been referred to, including some of the authors’ work on this topic. The main focus is the divergent results in the field and the important differences between the study population, the type of supplements and fresh marine sources, the proportion of EPA versus DHA dosages, and the duration of supplementation in clinical trials. We conclude that daily intake of at least 1 g of EPA + DHA may improve a dysmetabolic state in the population. The potential to reduce the risk and progression of atherothrombotic heart disease is still a matter of debate. |
| first_indexed | 2024-03-10T15:55:56Z |
| format | Article |
| id | doaj.art-74c9f477da5f495ebaf85a8d824edc0a |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-10T15:55:56Z |
| publishDate | 2020-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-74c9f477da5f495ebaf85a8d824edc0a2023-11-20T15:41:30ZengMDPI AGNutrients2072-66432020-09-011210301410.3390/nu12103014Very Long Chain Marine <i>n</i>-3 Polyunsaturated Fatty Acids in Atherothrombotic Heart Disease. A Brief Review, with a Focus on Metabolic EffectsHarald Arnesen0Peder L. Myhre1Ingebjørg Seljeflot2Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevål, Pb 4956 Nydalen, 0424 Oslo, NorwayFaculty of Medicine, University of Oslo, 0424 Oslo, NorwayCenter for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevål, Pb 4956 Nydalen, 0424 Oslo, NorwayThe global burden of atherothrombotic heart disease should be considered as a life-style disorder where differences in dietary habits and related risk factors like limited physical activity and adiposity together play important roles. Related metabolic changes have been scientifically elucidated in recent decades, and the role of the very-long-chain marine fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been much focused on, especially their possible effects on processes like inflammation and thrombosis. In the present brief review of related metabolic mechanisms, the effects of these fatty acids in a clinical setting have been referred to, including some of the authors’ work on this topic. The main focus is the divergent results in the field and the important differences between the study population, the type of supplements and fresh marine sources, the proportion of EPA versus DHA dosages, and the duration of supplementation in clinical trials. We conclude that daily intake of at least 1 g of EPA + DHA may improve a dysmetabolic state in the population. The potential to reduce the risk and progression of atherothrombotic heart disease is still a matter of debate.https://www.mdpi.com/2072-6643/12/10/3014omega-3 fatty acidsmetabolisminflammationatherothrombosisclinical trials |
| spellingShingle | Harald Arnesen Peder L. Myhre Ingebjørg Seljeflot Very Long Chain Marine <i>n</i>-3 Polyunsaturated Fatty Acids in Atherothrombotic Heart Disease. A Brief Review, with a Focus on Metabolic Effects Nutrients omega-3 fatty acids metabolism inflammation atherothrombosis clinical trials |
| title | Very Long Chain Marine <i>n</i>-3 Polyunsaturated Fatty Acids in Atherothrombotic Heart Disease. A Brief Review, with a Focus on Metabolic Effects |
| title_full | Very Long Chain Marine <i>n</i>-3 Polyunsaturated Fatty Acids in Atherothrombotic Heart Disease. A Brief Review, with a Focus on Metabolic Effects |
| title_fullStr | Very Long Chain Marine <i>n</i>-3 Polyunsaturated Fatty Acids in Atherothrombotic Heart Disease. A Brief Review, with a Focus on Metabolic Effects |
| title_full_unstemmed | Very Long Chain Marine <i>n</i>-3 Polyunsaturated Fatty Acids in Atherothrombotic Heart Disease. A Brief Review, with a Focus on Metabolic Effects |
| title_short | Very Long Chain Marine <i>n</i>-3 Polyunsaturated Fatty Acids in Atherothrombotic Heart Disease. A Brief Review, with a Focus on Metabolic Effects |
| title_sort | very long chain marine i n i 3 polyunsaturated fatty acids in atherothrombotic heart disease a brief review with a focus on metabolic effects |
| topic | omega-3 fatty acids metabolism inflammation atherothrombosis clinical trials |
| url | https://www.mdpi.com/2072-6643/12/10/3014 |
| work_keys_str_mv | AT haraldarnesen verylongchainmarineini3polyunsaturatedfattyacidsinatherothromboticheartdiseaseabriefreviewwithafocusonmetaboliceffects AT pederlmyhre verylongchainmarineini3polyunsaturatedfattyacidsinatherothromboticheartdiseaseabriefreviewwithafocusonmetaboliceffects AT ingebjørgseljeflot verylongchainmarineini3polyunsaturatedfattyacidsinatherothromboticheartdiseaseabriefreviewwithafocusonmetaboliceffects |